{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:26:24Z","timestamp":1778883984366,"version":"3.51.4"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004329","name":"Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jneuroim.2021.577505","type":"journal-article","created":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T06:46:10Z","timestamp":1611989170000},"page":"577505","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Natalizumab induced blood eosinophilia: A retrospective pharmacovigilance cohort study and review of the literature"],"prefix":"10.1016","volume":"353","author":[{"given":"L.","family":"Diem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Hoepner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bagnoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Salmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Friedli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.jneuroim.2021.577505_bb0005","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1212\/WNL.0b013e318233b391","article-title":"Hypereosinophilia in patients with multiple sclerosis treated with natalizumab","volume":"77","author":"Abbas","year":"2011","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jneuroim.2021.577505_bb0010","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5070\/D32W71S2MX","article-title":"Generalized Skin Drug Eruption to Natalizumab in a Patient With Multiple Sclerosis","volume":"16","author":"Andr\u00e9","year":"2010","journal-title":"Dermatol. Online J."},{"key":"10.1016\/j.jneuroim.2021.577505_bb0015","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1007\/s10620-019-05704-5","article-title":"Resolution of refractory eosinophilic esophagitis with the leukocyte-trafficking inhibitor Natalizumab","volume":"64","author":"Beales","year":"2019","journal-title":"Dig. Dis. Sci."},{"issue":"1","key":"10.1016\/j.jneuroim.2021.577505_bb0020","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2310\/7750.2013.13026","article-title":"Eosinophilic fasciitis occurring under treatment with natalizumab for multiple sclerosis","volume":"18","author":"Bujold","year":"2014","journal-title":"J. Cutan Med. Surg."},{"issue":"3","key":"10.1016\/j.jneuroim.2021.577505_bb0025","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4103\/1817-1737.185762","article-title":"Pulmonary eosinophilia associated to treatment with natalizumab","volume":"11","author":"Curto","year":"2016","journal-title":"Ann. Thorac. Med."},{"key":"10.1016\/j.jneuroim.2021.577505_bb0030","series-title":"Presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)","first-page":"P899","article-title":"Hypereosinophilia under natalizumab in a French cohort of MS patients","author":"Florek","year":"2010"},{"issue":"13","key":"10.1016\/j.jneuroim.2021.577505_bb0035","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s40265-013-0102-7","article-title":"Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis","volume":"73","author":"McCormack","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.jneuroim.2021.577505_bb0040","series-title":"Eosinophilia in Patients Treated with Disease Modifying Therapies. Posters, Congress of the European Committee for Treatment and Research in Multiple Sclerosis","author":"Mihalova","year":"2015"},{"issue":"1","key":"10.1016\/j.jneuroim.2021.577505_bb0045","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/BOR.0000000000000014","article-title":"Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis","volume":"26","author":"Pendergraft","year":"2014","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.jneuroim.2021.577505_bb0050","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2021.577505_bb0055","series-title":"Hypereosinophilia with Natalizumab","author":"Rocher","year":"2010"},{"key":"10.1016\/j.jneuroim.2021.577505_bb0060","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.2147\/TCRM.S225832","article-title":"Eosinophilic pneumonia associated with Natalizumab in a patient with multiple sclerosis: a case report and literature review","volume":"15","author":"Yasuda","year":"2019","journal-title":"Ther. Clin. Risk Manag."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572821000321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572821000321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:37:46Z","timestamp":1759048666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572821000321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":12,"alternative-id":["S0165572821000321"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577505","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natalizumab induced blood eosinophilia: A retrospective pharmacovigilance cohort study and review of the literature","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577505","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"577505"}}